Cerebrolysin

What is Cerebrolysin?

Cerebrolysin is a peptide preparation derived from porcine brain tissue that mimics the action of naturally occurring neurotrophic factors. It has been approved in over 40 countries for the treatment of stroke, traumatic brain injury, and dementia. It contains a mixture of low-molecular-weight peptides and free amino acids that can cross the blood-brain barrier.

What Cerebrolysin Is Investigated For

Cerebrolysin is a porcine brain-derived peptide preparation with the deepest clinical evidence base of any peptide in this reference outside the FDA-approved incretins — approved in over 40 countries for acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease, supported by multiple large randomized trials and meta-analyses. The strongest evidence is for stroke recovery and rehabilitation, where the CARS trials and multiple meta-analyses document modest but measurable motor-recovery benefits, and for vascular dementia and mild-to-moderate Alzheimer's, where cognitive endpoint improvements have been reported across several RCTs. The honest caveats are real and important: trial results have been mixed, with the large CASTA stroke trial failing to meet its primary endpoint; effect sizes in meta-analyses are modest rather than transformative; much of the literature is manufacturer-sponsored or concentrated in Russian, Chinese, and CIS research networks; and independent Western regulatory confirmation has not occurred — Cerebrolysin has never been FDA-approved. It is also a heterogeneous biological preparation (~15% peptides, ~85% free amino acids from porcine brain tissue) rather than a single defined peptide, which matters for interpreting efficacy data and distinguishing the branded product from unverified imitations.

History & Discovery

Cerebrolysin was developed by the Austrian pharmaceutical company EVER Neuro Pharma (originally Ebewe) beginning in the 1970s, with clinical use accelerating through the 1980s and 1990s. The preparation is produced by controlled enzymatic hydrolysis of porcine brain tissue, yielding a mixture of low-molecular-weight peptides (roughly 15 percent) and free amino acids (roughly 85 percent), filtered to remove larger proteins. The claim embedded in the product design is that this mixture contains or mimics multiple endogenous neurotrophic factors — BDNF, GDNF, NGF, CNTF — in a form small enough to cross the blood-brain barrier after parenteral administration. Cerebrolysin is unusual among the peptides in this reference: it is not a single defined molecule but a complex biological preparation, and it has been through an extensive set of randomized controlled trials — including the CASTA trial series in ischemic stroke and multiple Alzheimer's disease trials. Regulatory approval followed in Russia, China, Austria, and numerous CIS countries; today the product is registered in over 40 jurisdictions for indications including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. It has never received FDA approval in the United States, where the combination of a complex biologic of animal origin and evolving standards for neurological trial endpoints has kept it outside the approved formulary. Clinical trial results have been mixed: some large stroke trials (notably CASTA) did not meet their primary endpoints, while subgroup and later-phase analyses and meta-analyses have reported modest benefits in motor recovery and cognitive endpoints. The evidence is the strongest of any peptide in this reference, but the effect sizes are modest and the regulatory verdicts are jurisdiction-dependent.

How It Works

Cerebrolysin provides the brain with building blocks and growth signals similar to those naturally produced during brain development. It helps protect existing brain cells and may support the growth of new neural connections after injury.

Cerebrolysin mimics the action of endogenous neurotrophic factors including BDNF, GDNF, NGF, and CNTF. It promotes neuronal survival through anti-apoptotic mechanisms, enhances synaptic plasticity and neurogenesis, reduces amyloid-beta aggregation, and modulates GSK-3β activity. The peptide mixture crosses the blood-brain barrier and has been shown to reduce infarct volume in stroke models and improve cognitive scores in dementia trials.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cerebrolysin:

• 01Replication of efficacy findings across independent research groups and regulatory regions — much of the clinical literature is concentrated in manufacturer-sponsored trials or in Russian, Chinese, and CIS clinical networks, and independent Western regulatory confirmation has not occurred.
• 02Mechanism of action at the component level — Cerebrolysin is a heterogeneous preparation and the specific peptides or peptide combinations responsible for observed clinical effects are not fully identified.
• 03Comparative effectiveness vs. standard stroke rehabilitation alone and vs. other neuroprotective agents — head-to-head trials are limited.
• 04Long-term outcomes beyond 12 months after a treatment course — recent propensity-matched cohort work has begun to characterize 12-month functional recovery after thrombectomy + Cerebrolysin, but extended follow-up across the broader indication set remains inconsistent.
• 05Standardization of dosing across indications — the range of 5–50 mL/day across approved indications reflects empirical practice rather than rigorous dose-finding trials.
• 06Optimal repeat-course interval for chronic neurodegenerative indications (vascular dementia, Alzheimer's) has not been rigorously established.

Forms & Administration

Cerebrolysin is administered via intravenous or intramuscular injection. Treatment courses typically last 10-20 days with daily infusions. It requires clinical administration. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Cerebrolysin is not FDA-approved in the United States. It is approved in Russia, China, Austria, and over 40 other countries for specified neurological indications under their national regulatory frameworks. International approval does not constitute FDA approval. Any use outside jurisdictions where it is approved, or outside the approved indications, is not authorized medical care.

Timeline of Effects

Common Questions

Who Cerebrolysin Is NOT For

Drug & Supplement Interactions

Clinical drug interactions for Cerebrolysin have been studied more extensively than for most peptides in this reference, though the literature is still limited versus conventional drugs. The manufacturer's labeling and published studies flag a theoretical interaction with MAO inhibitors (including the class used for depression and in Parkinson's disease): Cerebrolysin is an amino-acid-rich preparation, and concurrent MAO inhibition could, in principle, alter monoamine handling. In practice, significant clinical interaction has not been consistently documented, but concurrent use is approached with caution. Co-administration with thrombolytics (alteplase) in acute ischemic stroke has been studied in dedicated trials (CEREHETIS series) and does not appear to increase hemorrhagic transformation rates, supporting combined use in reperfusion-eligible stroke patients. More recent meta-analytic and pooled-analysis work has extended this safety picture to mechanical thrombectomy — the modern standard of care for large-vessel-occlusion stroke — with adjunct Cerebrolysin showing functional-recovery benefit without increased hemorrhagic transformation across observational cohorts. Concurrent use with standard stroke rehabilitation, antihypertensives, statins, and antiplatelet agents has not shown problematic interactions in trial populations. Patients on any psychiatric medications, particularly MAOIs or complex antidepressant regimens, should have Cerebrolysin use reviewed by their prescribing clinician. Concurrent use with other nootropic peptides (Semax, Selank) is common in Russian clinical practice but has not been formally studied for interaction safety.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions